Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.45 -3.7%	$6.03	$2.33 ▼ $37.80	$6.63M	0.88	65,962 shs	57,587 shs
ALVR AlloVir	$3.56 +15.6%	$2.57	$7.96 ▼ $24.15	$17.95M	0.63	15,685 shs	328,619 shs
AYLA Ayala Pharmaceuticals	$0.50	$0.48	$0.36 ▼ $7.31	$7.46M	1.98	76,300 shs	N/A
FNCH Finch Therapeutics Group	$13.00 +6.1%	$12.68	$10.15 ▼ $15.85	$20.88M	1.19	2,182 shs	287 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+0.99%	-5.58%	-19.37%	-72.21%	-92.85%
ALVR AlloVir	+20.31%	+19.84%	+5.30%	+4.05%	-82.38%
AYLA Ayala Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
FNCH Finch Therapeutics Group	+6.12%	-3.56%	+4.00%	-3.70%	+1.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.0871 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AYLA Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	0.3238 of 5 stars	0.0	3.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	11,138.25% Upside
ALVR AlloVir	0.00	N/A	N/A	N/A
AYLA Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	54.78	N/A	N/A	$0.20 per share	12.24
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
AYLA Ayala Pharmaceuticals	$3.51M	2.13	N/A	N/A	$2.45 per share	0.21
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
ALVR AlloVir	-$190.42M	-$20.23	N/A	∞	N/A	N/A	-71.03%	-61.27%	11/10/2025 (Estimated)
AYLA Ayala Pharmaceuticals	-$40.25M	-$2.52	N/A	N/A	N/A	-2,341.69%	-182.13%	-139.83%	N/A
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
AYLA Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
ALVR AlloVir	N/A	86.78	86.78
AYLA Ayala Pharmaceuticals	N/A	2.28	2.28
FNCH Finch Therapeutics Group	N/A	3.87	3.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
ALVR AlloVir	66.05%
AYLA Ayala Pharmaceuticals	22.10%
FNCH Finch Therapeutics Group	21.77%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
ALVR AlloVir	32.07%
AYLA Ayala Pharmaceuticals	3.60%
FNCH Finch Therapeutics Group	44.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	2.71 million	68.74 million	Not Optionable
ALVR AlloVir	110	5.04 million	3.43 million	Optionable
AYLA Ayala Pharmaceuticals	35	14.82 million	14.29 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data

AYLA, FNCH, ALVR, and AIM Headlines

Recent News About These Companies

Critical Comparison: Finch Therapeutics Group (NASDAQ:FNCH) vs. Protalix BioTherapeutics (NYSE:PLX)

August 26 at 2:08 AM | americanbankingnews.com

FNCH - Finch Therapeutics Group Inc Price vs Fair Value - Morningstar

July 4, 2025 | morningstar.comM

FNCH Finch Therapeutics Group, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Arquitos Capital's Largest Holdings For Q1 2025

May 1, 2025 | seekingalpha.com

Arquitos Capital Management Q4 2024 Commentary

February 5, 2025 | seekingalpha.com

Finch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC Deregistration

October 23, 2024 | finanznachrichten.de

Finch Therapeutics announces Nasdaq delisting, SEC deregistration

October 22, 2024 | markets.businessinsider.com

Finch Therapeutics Group to Delist from Nasdaq

October 22, 2024 | markets.businessinsider.com

Finch Announces Delisting from Nasdaq and SEC Deregistration

October 21, 2024 | globenewswire.com

Finch Therapeutics Gr (OTC:FNCH) Stock Quotes, Forecast and News Summary

October 5, 2024 | benzinga.com

Finch wins US jury trial against Ferring over fecal-transplant patents

August 10, 2024 | reuters.com

It is likely that Finch Therapeutics Group Inc (FNCH) Stock will grow up

May 25, 2024 | bovnews.comB

Finch Therapeutics Group (NASDAQ: FNCH)

April 14, 2024 | fool.com

Jeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Stock

March 31, 2024 | insidertrades.com

FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023

March 25, 2024 | investorplace.com

Finch Therapeutics Group Inc (FNCH)

March 7, 2024 | investing.com

Finch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest Report

February 22, 2024 | benzinga.com

Finch Therapeutics Group Inc FNCH

November 5, 2023 | morningstar.comM

Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)

August 21, 2023 | markets.businessinsider.com

Finch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common Stock

June 9, 2023 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYLA, FNCH, ALVR, and AIM Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.45 -0.09 (-3.66%)

Closing price 03:59 PM Eastern

Extended Trading

$2.51 +0.06 (+2.57%)

As of 05:58 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AlloVir NASDAQ:ALVR

$3.56 +0.48 (+15.58%)

As of 08/28/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Ayala Pharmaceuticals NASDAQ:AYLA

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Finch Therapeutics Group NASDAQ:FNCH

$13.00 +0.75 (+6.12%)

As of 08/28/2025 03:58 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time